Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Mechanism of Action of Chemical Category 1 Innovative Drug GMDTC on Neuropsychiatric Behavior in Cadmium-exposed People

NCT06572566 is registered in ClinicalTrials.gov with Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06572566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06572566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Mechanism of Action of Chemical Category 1 Innovative Drug GMDTC on Neuropsychiatric Behavior in Cadmium-exposed People
Lead sponsor
Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
January 8, 2024
Completion date
March 30, 2026
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cadmium exceeds the standard